Treatment
Combination therapy clinical trials
We’re tracking 888 recruiting studies that include Combination therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT05682482RecruitingPhase 3
Combination T4/T3 vs T4 alone for autoimmune hypothyroid fatigue
This trial compares adding T3 (plus T4) versus taking only T4 to see if it improves severe ongoing tiredness in people with autoimmune hypothyroidism. You would stay on your thyroid medicine plan during the study and be monitored with blood tests and health checks.
Almere StadAges 18 years+ - NCT07484724RecruitingPhase 2
JS212 combination therapy for advanced esophageal cancer
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07448922RecruitingPhase 2
Study of SKB518 for advanced gynecologic cancers
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
ChongqingAges 18–75 - NCT06030258RecruitingPhase 1/Phase 2
Study of IN10018 plus standard chemo for extensive-stage small cell lung cancer
This trial tests a new drug called IN10018 combined with standard chemotherapy (carboplatin and etoposide) and an immunotherapy (anti-PD-1/L1) for people with extensive-stage small cell lung cancer (ES-SCLC) who have not yet been treated. The goal is to see if adding IN10018 helps shrink tumors or slow the cancer's growth.
JinanAges 18–75 - NCT07483554RecruitingPhase 2
IBI343 combination therapy for advanced solid tumors
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07407504RecruitingPhase 1
GenSci145 for advanced solid tumors with PIK3CA mutation
This trial tests a new oral drug, GenSci145, alone or with other drugs, for people whose advanced cancer has a PIK3CA gene change and has grown after standard treatments. It aims to see if this drug can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07309276RecruitingPhase 2
Study of JS212 for advanced lung cancer
This trial tests a new drug called JS212 combined with other treatments for people with advanced or spreading lung cancer. It aims to see if the combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07171606RecruitingPhase 2
Study of a new drug for advanced lung cancer
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
ShanghaiAges 18–75 - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05765851RecruitingPhase 1
HER2-targeting drug study for advanced solid tumors
This Phase 1 trial tests a combination of medicines (including DS-1103a) for people with advanced, hard-to-remove (unresectable) or metastatic solid tumors that have HER2 changes. Because it’s an early safety/dose study, it mainly aims to find the right dose and see how the tumor responds.
Sarasota, FloridaAges 18 years+ - NCT06833593Recruiting
Antibiotic combinations for enterococcus blood infection
This study looks at whether using two or more antibiotics together works better than one alone for a specific type of blood infection caused by Enterococcus faecalis bacteria. The goal is to find the safest and most effective way to treat this infection and improve outcomes for patients.
Bologna, BolognaAges 18 years+ - NCT07097935RecruitingPhase 1/Phase 2
Study of HS-10516 combo therapy for advanced kidney cancer
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05994131RecruitingPhase 1/Phase 2
IN10018 plus targeted therapy for EGFR-mutant lung cancer
This trial tests a new drug called IN10018 combined with a targeted therapy (third-generation EGFR-TKI) for people with advanced EGFR-mutant non-small cell lung cancer. It's designed for different stages of treatment, from first-time therapy to after other treatments have stopped working.
ShanghaiAges 18 years+ - NCT05825157Recruiting
Tested combined treatment for arm swelling after cancer
This study looks at a combination treatment to improve swelling in one arm caused by lymphedema. You may be a good candidate if your arm swelling has not fully improved with standard compression therapy and you are able to have surgery.
Palo Alto, CaliforniaAges 18–75 - NCT06868732RecruitingPhase 1
A new drug combination for advanced non-small cell lung cancer
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06953323RecruitingPhase 1/Phase 2
Study of WJB001 combined therapy for advanced solid tumors
This trial tests a new drug combination for people with advanced solid tumors that are no longer responding to standard treatments. It focuses on patients whose tumors have high levels of a protein called CCNE1, particularly for certain ovarian, fallopian tube, peritoneal, and uterine cancers.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07283367RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new combination of targeted therapies for people with advanced colorectal cancer that has a certain genetic pattern (non-MSI-H, no BRAF V600E mutation). It aims to see if the combination can shrink tumors or slow the cancer's growth.
GuangzhouAges 18 years+ - NCT06942234RecruitingPhase 1/Phase 2
Study of JSKN016 for advanced HER2-negative breast cancer
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
ShanghaiAges 18–75 - NCT06683885RecruitingPhase 1/Phase 2
Targeted drug combo for elderly DLBCL patients
This trial tests a combination of targeted drugs (Obutinib or Decitabine) with standard chemo (Rituximab, Cyclophosphamide, Prednisone) for elderly patients with newly diagnosed diffuse large B-cell lymphoma who cannot handle full-dose chemotherapy. The goal is to see if this approach is safer and works as well.
Zhengzhou, HenanAges 65 years+ - NCT06734533Recruiting
Anlotinib combo for HR+ breast cancer that has spread
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Changsha, HunanAges 18–75 - NCT06048484RecruitingPhase 2
Combination therapy for localized pancreatic cancer
This trial tests a combination of drugs for people with localized pancreatic cancer who have already completed 8 cycles of modified FOLFIRINOX chemotherapy before surgery. The goal is to see if adding these drugs after chemo and radiation helps improve outcomes.
Lake Success, New YorkAges 18 years+ - NCT06697197RecruitingPhase 1/Phase 2
Study of experimental drug BMS-986482 for advanced solid tumors
This study tests a new drug (BMS-986482) alone or with other treatments for people with advanced solid tumors that haven't responded to standard therapies. The goal is to see if this drug can shrink tumors or slow their growth.
Irvine, CaliforniaAges 18 years+ - NCT05410145RecruitingPhase 1/Phase 2
Study drug for advanced KRAS G12C solid tumors
This trial tests D3S-001 (alone or with other treatments) in people with advanced solid cancers that have a KRAS G12C mutation. It’s mainly aimed at early safety and learning whether the treatment can shrink or control tumors.
Orange, CaliforniaAges 18 years+ - NCT06520891Recruiting
Statin with SGLT2i for ischemic heart disease
This study tests if taking a statin along with an SGLT2 inhibitor (a diabetes drug that also helps the heart) works better for people with heart disease caused by blocked arteries. The goal is to improve heart function with this combination therapy.
Al Fayyum, Faiyum GovernorateAges 50–80
Common questions
- Are there clinical trials studying Combination therapy?
- Yes. Clin2 currently lists 888 recruiting studies that include Combination therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Combination therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Combination therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Combination therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.